JP2010537989A5 - - Google Patents

Download PDF

Info

Publication number
JP2010537989A5
JP2010537989A5 JP2010522977A JP2010522977A JP2010537989A5 JP 2010537989 A5 JP2010537989 A5 JP 2010537989A5 JP 2010522977 A JP2010522977 A JP 2010522977A JP 2010522977 A JP2010522977 A JP 2010522977A JP 2010537989 A5 JP2010537989 A5 JP 2010537989A5
Authority
JP
Japan
Prior art keywords
composition
buprenorphine
daltons
polyethylene glycol
peg
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2010522977A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010537989A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2008/010318 external-priority patent/WO2009032246A2/en
Publication of JP2010537989A publication Critical patent/JP2010537989A/ja
Publication of JP2010537989A5 publication Critical patent/JP2010537989A5/ja
Pending legal-status Critical Current

Links

JP2010522977A 2007-09-03 2008-09-02 難溶性薬物の組成物及び送達方法 Pending JP2010537989A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US96967207P 2007-09-03 2007-09-03
PCT/US2008/010318 WO2009032246A2 (en) 2007-09-03 2008-09-02 Particulate compositions for delivery of poorly soluble drugs

Publications (2)

Publication Number Publication Date
JP2010537989A JP2010537989A (ja) 2010-12-09
JP2010537989A5 true JP2010537989A5 (enExample) 2011-10-20

Family

ID=40377549

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2010522977A Pending JP2010537989A (ja) 2007-09-03 2008-09-02 難溶性薬物の組成物及び送達方法

Country Status (14)

Country Link
US (3) US8377479B2 (enExample)
EP (2) EP3064198A1 (enExample)
JP (1) JP2010537989A (enExample)
KR (1) KR101545874B1 (enExample)
AU (1) AU2008296971B2 (enExample)
CA (1) CA2699172C (enExample)
DK (1) DK2197429T3 (enExample)
ES (1) ES2572157T3 (enExample)
HK (1) HK1226306A1 (enExample)
HU (1) HUE027537T2 (enExample)
MX (1) MX2010002409A (enExample)
PL (1) PL2197429T3 (enExample)
SI (1) SI2197429T1 (enExample)
WO (1) WO2009032246A2 (enExample)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2939696T3 (en) * 2001-10-18 2016-05-23 Nektar Therapeutics Polymer Conjugates of Opioid Antagonists
US8852638B2 (en) 2005-09-30 2014-10-07 Durect Corporation Sustained release small molecule drug formulation
CN101801415B (zh) 2007-05-25 2015-09-23 Rb医药品有限公司 利培酮化合物的持续递送制剂
EP3064198A1 (en) * 2007-09-03 2016-09-07 Nanotherapeutics, Inc. Particulate compositions for delivery of poorly soluble drugs
WO2010085641A1 (en) * 2009-01-22 2010-07-29 Noramco, Inc. Process for preparing particles of opioids and compositions produced thereby
US20100273730A1 (en) * 2009-04-27 2010-10-28 Innopharmax, Inc. Self-emulsifying pharmaceutical compositions of hydrophilic drugs and preparation thereof
US9125867B2 (en) * 2010-02-24 2015-09-08 Invincible Biotechnology Diversion- and/or abuse-resistant compositions and methods for making the same
GB2481017B (en) * 2010-06-08 2015-01-07 Rb Pharmaceuticals Ltd Microparticle buprenorphine suspension
US9272044B2 (en) 2010-06-08 2016-03-01 Indivior Uk Limited Injectable flowable composition buprenorphine
CN108703948A (zh) 2010-10-21 2018-10-26 Rtu制药有限责任公司 即用型酮咯酸注射液
CA3042642A1 (en) 2013-08-12 2015-02-19 Pharmaceutical Manufacturing Research Services, Inc. Extruded immediate release abuse deterrent pill
WO2015095391A1 (en) 2013-12-17 2015-06-25 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
US9492444B2 (en) 2013-12-17 2016-11-15 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
GB201404139D0 (en) 2014-03-10 2014-04-23 Rb Pharmaceuticals Ltd Sustained release buprenorphine solution formulations
EP3169315B1 (en) 2014-07-17 2020-06-24 Pharmaceutical Manufacturing Research Services, Inc. Immediate release abuse deterrent liquid fill dosage form
WO2016064873A1 (en) 2014-10-20 2016-04-28 Pharmaceutical Manufacturing Research Services, Inc. Extended release abuse deterrent liquid fill dosage form
MX2017005883A (es) 2014-11-04 2017-11-28 Innopharmax Inc Administracion oral de farmacos inestables o deficientemente absorbidos.
AU2015341490C1 (en) 2014-11-07 2021-03-11 Indivior Uk Limited Buprenorphine dosing regimens
US10646484B2 (en) 2017-06-16 2020-05-12 Indivior Uk Limited Methods to treat opioid use disorder
WO2019064026A1 (en) 2017-09-29 2019-04-04 Orexo Ab NEW PHARMACEUTICAL COMPOSITIONS
EP3727384A4 (en) 2017-12-20 2021-11-03 Purdue Pharma L.P. ABUSE-DISSUASIVE MORPHINE SULPHATE FORMES
GB201904767D0 (en) 2019-04-04 2019-05-22 Orexo Ab New pharmaceutical compositions
WO2021163252A1 (en) 2020-02-14 2021-08-19 Teikoku Pharma Usa, Inc. Topical naloxone compositions and methods for using the same
GB202019335D0 (en) * 2020-12-08 2021-01-20 Artelo Biosciences Ltd Pharmaceutical compositions
WO2024253935A1 (en) 2023-06-05 2024-12-12 Nanopharmaceutics, Inc. Compositions and methods for oral delivery of sustained release crystalline prx-3140

Family Cites Families (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA987588A (en) * 1970-01-02 1976-04-20 Sidney Riegelman Solid dispersions of drugs
DE2400819C2 (de) 1974-01-09 1982-04-22 Bayer Ag, 5090 Leverkusen Verfahren zur Herstellung fester Zubereitungen von schwerlöslichen Arzneimittelwirkstoffen in feinster Verteilung
US4722941A (en) * 1978-06-07 1988-02-02 Kali-Chemie Pharma Gmbh Readily absorbable pharmaceutical compositions of per se poorly absorbable pharmacologically active agents and preparation thereof
EP0012523B2 (en) 1978-11-20 1988-02-03 American Home Products Corporation Therapeutic compositions with enhanced bioavailability and process for their preparation
US4525339A (en) * 1982-10-15 1985-06-25 Hoffmann-La Roche Inc. Enteric coated oral dosage form
JPS6163614A (ja) * 1984-09-04 1986-04-01 Yamanouchi Pharmaceut Co Ltd 難溶性薬物の溶解速度向上方法
GB8514665D0 (en) * 1985-06-11 1985-07-10 Eroceltique Sa Oral pharmaceutical composition
US5190748A (en) * 1988-11-22 1993-03-02 Hoffmann-La Roche Inc. Absorption enhancement of antibiotics
DK469989D0 (da) * 1989-09-22 1989-09-22 Bukh Meditec Farmaceutisk praeparat
AU7496991A (en) * 1990-03-20 1991-10-21 Otsuka Pharmaceutical Co., Ltd. Liposome preparation
US5145684A (en) * 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
FR2735658B1 (fr) * 1995-06-21 1997-09-12 Capsulis Encapsulation de composes a usage alimentaire par des tensioactifs
US5681585A (en) * 1991-12-24 1997-10-28 Euro-Celtique, S.A. Stabilized controlled release substrate having a coating derived from an aqueous dispersion of hydrophobic polymer
US6235313B1 (en) * 1992-04-24 2001-05-22 Brown University Research Foundation Bioadhesive microspheres and their use as drug delivery and imaging systems
US5352459A (en) * 1992-12-16 1994-10-04 Sterling Winthrop Inc. Use of purified surface modifiers to prevent particle aggregation during sterilization
US5981719A (en) * 1993-03-09 1999-11-09 Epic Therapeutics, Inc. Macromolecular microparticles and methods of production and use
US5318781A (en) * 1993-04-06 1994-06-07 Hoffmann-La Roche Inc. Absorption enhancement of antibiotics
IL110014A (en) 1993-07-01 1999-11-30 Euro Celtique Sa Solid controlled-release oral dosage forms of opioid analgesics
IE940292A1 (en) 1994-04-06 1995-10-18 Elan Corp Plc Biodegradable microcapsules and method for their manufacture
US5965161A (en) * 1994-11-04 1999-10-12 Euro-Celtique, S.A. Extruded multi-particulates
US6368586B1 (en) * 1996-01-26 2002-04-09 Brown University Research Foundation Methods and compositions for enhancing the bioadhesive properties of polymers
PT914097E (pt) * 1996-03-12 2002-06-28 Alza Corp Composicao e forma de dosagem compreendendo antagonista de opioide
GB9606188D0 (en) * 1996-03-23 1996-05-29 Danbiosyst Uk Pollysaccharide microspheres for the pulmonary delivery of drugs
EP0811374A1 (en) * 1996-05-29 1997-12-10 Pfizer Inc. Combination dosage form comprising cetirizine and pseudoephedrine
US5858531A (en) * 1996-10-24 1999-01-12 Bio Syntech Method for preparation of polymer microparticles free of organic solvent traces
US5948787A (en) * 1997-02-28 1999-09-07 Alza Corporation Compositions containing opiate analgesics
UA55507C2 (uk) * 1997-12-22 2003-04-15 Еро-Селтік, С.А. Лікарська форма для перорального введення та спосіб запобігання зловживанню пероральною опіоїдною композицією
WO1999032120A1 (en) * 1997-12-22 1999-07-01 Euro-Celtique, S.A. A method of preventing abuse of opioid dosage forms
FR2774910B1 (fr) * 1998-02-16 2001-09-07 Ethypharm Lab Prod Ethiques Microgranules de sulfate de morphine, procede de fabrication et preparations pharmaceutiques
US6190699B1 (en) * 1998-05-08 2001-02-20 Nzl Corporation Method of incorporating proteins or peptides into a matrix and administration thereof through mucosa
JP2000086509A (ja) * 1998-09-14 2000-03-28 Taisho Yakuhin Kogyo Kk ソファルコン含有製剤の製造方法
US8293277B2 (en) * 1998-10-01 2012-10-23 Alkermes Pharma Ireland Limited Controlled-release nanoparticulate compositions
US6733789B1 (en) * 1999-01-21 2004-05-11 Biovail Laboratories, Inc. Multiparticulate bisoprolol formulation
US6270806B1 (en) * 1999-03-03 2001-08-07 Elan Pharma International Limited Use of peg-derivatized lipids as surface stabilizers for nanoparticulate compositions
US6223455B1 (en) * 1999-05-03 2001-05-01 Acusphere, Inc. Spray drying apparatus and methods of use
US6406745B1 (en) * 1999-06-07 2002-06-18 Nanosphere, Inc. Methods for coating particles and particles produced thereby
CN100387228C (zh) * 1999-08-27 2008-05-14 布鲁克伍德药品公司 可注射的美沙酮、部分类鸦片激动剂或类鸦片拮抗剂微粒组合物及其用途
US6480524B1 (en) * 1999-09-13 2002-11-12 Nortel Networks Limited Multiple beam antenna
AR031682A1 (es) * 1999-11-19 2003-10-01 Reckitt Benckiser Helthcare Uk Composiciones farmaceuticas
EP2517710B1 (en) * 2000-02-08 2015-03-25 Euro-Celtique S.A. Tamper-resistant oral opioid agonist formulations
US6248360B1 (en) * 2000-06-21 2001-06-19 International Health Management Associates, Inc. Complexes to improve oral absorption of poorly absorbable antibiotics
ATE378039T1 (de) * 2000-06-27 2007-11-15 Vectura Ltd Herstellungsverfahren für partikel zur verwendung in einer arzneizusammensetzung
WO2002029990A1 (en) * 2000-10-05 2002-04-11 Samsung Electronics Co., Ltd Tstd apparatus and method for a tdd cdma mobile communication system
EP2932964A1 (en) * 2000-10-30 2015-10-21 Euro-Celtique S.A. Controlled release hydrocodone formulations
US20030044458A1 (en) * 2001-08-06 2003-03-06 Curtis Wright Oral dosage form comprising a therapeutic agent and an adverse-effect agent
US8501232B2 (en) * 2002-04-23 2013-08-06 Nanotherapeutics, Inc. Process of forming and modifying particles and compositions produced thereby
US7157102B1 (en) * 2002-05-31 2007-01-02 Biotek, Inc. Multi-layered microcapsules and method of preparing same
US20040110781A1 (en) * 2002-12-05 2004-06-10 Harmon Troy M. Pharmaceutical compositions containing indistinguishable drug components
US20040121003A1 (en) * 2002-12-19 2004-06-24 Acusphere, Inc. Methods for making pharmaceutical formulations comprising deagglomerated microparticles
US20040191301A1 (en) * 2003-03-27 2004-09-30 Van Duren Albert Philip Transdermal device having a phase change material
EP1610763A2 (en) * 2003-03-31 2006-01-04 Yissum Research Development Company Of The Hebrew University Of Jerusalem Stable liposomes or micelles comprising a sphingolipid and a peg-lipopolymer
DE10336400A1 (de) * 2003-08-06 2005-03-24 Grünenthal GmbH Gegen Missbrauch gesicherte Darreichungsform
US20050048115A1 (en) * 2003-08-27 2005-03-03 Murty Mangena Buprenorphine microspheres
IL159729A0 (en) * 2004-01-06 2004-06-20 Doron I Friedman Non-aqueous composition for oral delivery of insoluble bioactive agents
WO2005074890A1 (en) * 2004-01-30 2005-08-18 Pfizer Italia S.R.L. Semisolid matrix pharmaceutical formulations
ES2246694B1 (es) * 2004-04-29 2007-05-01 Instituto Cientifico Y Tecnologico De Navarra, S.A. Nanoparticulas pegiladas.
FR2878158B1 (fr) * 2004-11-24 2009-01-16 Flamel Technologies Sa Forme pharmaceutique orale, microparticulaire solide concue pour eviter le mesusage
JP2006232694A (ja) * 2005-02-23 2006-09-07 Univ Nihon 難溶性医薬とシクロデキストリン化合物からなる複合体及びその製造方法
WO2007003278A1 (en) * 2005-07-05 2007-01-11 Abbott-Gmbh & Co. Kg Composition and dosage form comprising a solid or semi-solid matrix
EP1922150A1 (en) * 2005-07-07 2008-05-21 Nanotherapeutics, Inc. Process for milling and preparing powders and compositions produced thereby
US20070020339A1 (en) * 2005-07-20 2007-01-25 Pharmorx Inc. Compositions and methods for controlling abuse of medications
EP3064198A1 (en) * 2007-09-03 2016-09-07 Nanotherapeutics, Inc. Particulate compositions for delivery of poorly soluble drugs

Similar Documents

Publication Publication Date Title
JP2010537989A5 (enExample)
JP2009143964A5 (enExample)
HRP20160368T1 (hr) Sublingvalni i bukalni filmom obložen pripravak
ES2572157T3 (es) Composiciones en forma de partículas para la administración de fármacos poco solubles
JP2012012418A5 (enExample)
JP2018162284A5 (ja) 複数の被覆された粒子を含む組成物及び医薬製剤
JP2015519330A5 (enExample)
HRP20171506T1 (hr) Tableta otporna na mijenjanje koja pruža neposredno oslobađanje lijeka
WO2013101897A3 (en) Improved compositions and methods for delivery of omeprazole plus acetylsalicylic acid
WO2009100181A3 (en) Absorbent ingestible agents and associated methods of manufacture and use
IL200171A (en) Actriib-derived variables, pharmaceutical preparations containing them and their uses for the preparation of medicines
Dua et al. Application of chitosan and its derivatives in nanocarrier based pulmonary drug delivery systems
JP2012528154A5 (enExample)
NZ629468A (en) Tamper resistant immediate release formulations
JP2012176990A5 (enExample)
JP2014515356A5 (enExample)
JP2013505233A5 (enExample)
WO2007086914A3 (en) Nanoparticulate clopidogrel formulations
NZ587897A (en) Drug delivery systems comprising weakly basic drugs and organic acids
JP2011157405A5 (enExample)
JP2012500786A5 (enExample)
IL210544A (en) Pharmaceuticals containing pyrazole derivatives, solid oral dosage forms containing them and their uses for drug preparation
HRP20161138T1 (hr) Farmaceutski pripravak za oralnu primjenu
HK1209371A1 (en) Oral and/or buccal composition in the form of a thin film of a weakly soluble active ingredient, method of preparing same and use of same
WO2011013032A3 (en) Method for the preparation of microparticles with efficient bioactive molecule incorporation